Testosterone Replacement Therapy Risks: What Your Doctor May Not Tell You
A thorough functional medicine guide to testosterone replacement therapy risks including cardiovascular, hematologic, hormonal, and psychological effects. Learn monitoring protocols to stay safe.
Sieu P. Truong, M.D. · Medical Doctor · · 8 min read
Key Takeaways
- ✓Most TRT risks are dose-dependent — physiologic doses carry significantly lower risk than supraphysiologic levels used in bodybuilding or poorly monitored clinics.
- ✓Polycythemia (elevated hematocrit) is the most common serious risk, affecting 5-15% of patients, and is fully manageable with regular CBC monitoring and dose adjustment.
- ✓TRT suppresses fertility in most men — sperm banking should be discussed before starting therapy for anyone who may want children.
- ✓The TRAVERSE trial (2023) showed no increased cardiovascular risk at physiologic doses, challenging decades of cardiovascular safety concerns.
- ✓Comprehensive lab monitoring at baseline, 6 weeks, 3 months, and every 6-12 months is the single most effective risk-reduction strategy.
Testosterone replacement therapy (TRT) has become one of the most prescribed hormone therapies in modern medicine, with millions of men — and increasingly, women — using it to address symptoms of low testosterone. The benefits can be life-changing: restored energy, improved mood, better body composition, sharper cognition, and renewed libido. With regard to the T-treated group, the calculated absolute risk for all CV events was 10% (123 events in 1223 men) versus the group not treated with T with a calculated risk of 21.2% (1587 events in 7486 men). (NIH)
But every powerful therapy comes with risks. And in the world of TRT, those risks are often either overstated by fearful practitioners or understated by enthusiastic clinics trying to sell you a protocol. Neither extreme serves you well.
This guide provides an honest, evidence-informed assessment of the real risks associated with testosterone replacement therapy — what they are, how likely they are, who is most vulnerable, and how proper monitoring can mitigate most of them. As functional medicine practitioners, we believe informed patients make better decisions.
Understanding the Risk Landscape
Before diving into specific risks, it's important to understand a few framing principles:
- Dose matters enormously. Most TRT risks are dose-dependent — they increase significantly at supraphysiologic levels and are minimal at well-monitored physiologic doses.
- Delivery method influences risk. Oral testosterone (methyltestosterone) carries liver risks that injectable, transdermal, and pellet forms do not.
- Individual biology determines vulnerability. Genetic predispositions, existing health conditions, and metabolic status all modify your personal risk profile.
- Monitoring prevents most serious complications. The majority of TRT risks are detectable through routine lab work before they become clinical problems.
Cardiovascular Risks
The Controversy
The relationship between TRT and cardiovascular health has been the most debated topic in hormone therapy for over a decade. Early observational studies raised alarms about increased heart attack and stroke risk. More recent data — including the landmark TRAVERSE trial (2023), a large randomized controlled trial — showed no increased cardiovascular risk in men with hypogonadism and pre-existing or high risk for cardiovascular disease receiving TRT.
The current clinical consensus is nuanced:
- Physiologic-dose TRT does not appear to increase cardiovascular events in appropriately selected patients
- Supraphysiologic doses (as used in bodybuilding) clearly increase cardiovascular risk
- TRT may actually improve cardiovascular risk factors: insulin sensitivity, body composition, lipid profiles, and inflammatory markers
- The first 6-12 months of therapy may represent a period of slightly elevated risk in men with significant pre-existing cardiovascular disease
Risk Mitigation
| Risk Factor | Monitoring | Frequency | Action Threshold |
|---|---|---|---|
| Blood pressure | Home BP monitoring | Weekly initially, then monthly | >140/90 sustained |
| Lipid panel | Fasting lipids | Baseline, 3 months, then annually | LDL increase >30% |
| Hematocrit | CBC | Baseline, 6 weeks, 3 months, then every 6 months | >54% |
| Inflammatory markers | hs-CRP | Baseline, 6 months, annually | >3.0 mg/L |
Hematologic Risks: Polycythemia (Elevated Red Blood Cells)
This is the most common and clinically significant risk of TRT. Testosterone stimulates erythropoiesis — the production of red blood cells — through its effects on erythropoietin and iron metabolism. This is a physiologic response (it's one reason men naturally have higher hemoglobin than women), but TRT can push it beyond safe limits.
What Happens
Elevated hematocrit (the percentage of blood volume occupied by red blood cells) increases blood viscosity — making blood "thicker" and harder to pump. This raises the risk of:
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Stroke
- Heart attack
How Common Is It?
Clinically significant polycythemia (hematocrit >54%) occurs in approximately 5-15% of men on TRT, depending on the delivery method:
| Delivery Method | Polycythemia Risk | Explanation |
|---|---|---|
| Injectable (cypionate/enanthate) | 10-15% | Peak levels stimulate more erythropoiesis |
| Pellets | 5-10% | More steady delivery, moderate risk |
| Topical (gel/cream) | 3-5% | Lowest peak levels, least stimulation |
| Nasal (Natesto) | 1-3% | Pulsatile, low systemic exposure |
Management
- Hematocrit 50-54%: Increase hydration, reduce dose, increase injection frequency (to lower peaks), recheck in 4-6 weeks
- Hematocrit >54%: Hold TRT, consider therapeutic phlebotomy (blood donation), investigate contributing factors (sleep apnea, dehydration, smoking)
- Hematocrit >58%: Urgent — stop TRT, therapeutic phlebotomy, hematology consult
Hormonal Disruption Risks
Fertility Suppression
This may be the most underappreciated risk of TRT, particularly for younger men. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, dramatically reducing or eliminating sperm production. In many men, TRT functions as male contraception.
- Sperm count drops to zero (azoospermia) in approximately 40-60% of men on TRT within 3-6 months
- Recovery after stopping TRT typically takes 6-12 months, but is not guaranteed
- Some men never fully recover fertility, particularly after prolonged use (>2 years)
Critical point: Any man who may want children in the future should discuss fertility preservation (sperm banking) before starting TRT. Alternatives like clomiphene citrate or enclomiphene can raise testosterone while preserving fertility.
Testicular Atrophy
When exogenous testosterone suppresses LH and FSH, the testes lose their primary stimulation. They shrink — typically by 20-40% over the first year of TRT. This is generally reversible if TRT is stopped, but recovery may be incomplete after prolonged use.
Some practitioners co-prescribe hCG (human chorionic gonadotropin) at 500-1000 IU two to three times weekly to maintain testicular size and intratesticular testosterone production. This approach is common in functional medicine and fertility-focused protocols.
Estrogen Elevation
Testosterone converts to estradiol via the aromatase enzyme, primarily in adipose (fat) tissue. Men with higher body fat percentages tend to aromatize more testosterone into estrogen, potentially causing:
- Gynecomastia (breast tissue growth)
- Water retention and bloating
- Mood changes, emotional lability
- Reduced libido (paradoxically)
| Estradiol Level (Men) | Interpretation | Action |
|---|---|---|
| <15 pg/mL | Too low — joint pain, low mood, bone risk | Reduce AI if using; increase T dose |
| 15-35 pg/mL | Optimal functional range | None — maintain |
| 35-50 pg/mL | Mildly elevated — monitor symptoms | Consider dose reduction, weight loss, DIM/calcium-d-glucarate |
| >50 pg/mL | Elevated — increased side effect risk | Dose reduction, lower body fat, consider low-dose AI short-term |
Prostate Risks
The Historical Fear
For decades, the medical establishment operated under the assumption that testosterone "feeds" prostate cancer. This was based on Charles Huggins' 1941 Nobel Prize-winning work showing that castration shrank prostate tumors. The logical extension — that adding testosterone would grow prostate cancer — became dogma for 70 years.
The Modern Understanding
The "saturation model," proposed by Abraham Morgentaler, MD, has fundamentally changed this understanding. The prostate appears to have a threshold for androgen sensitivity — once androgen receptors are saturated (which occurs at relatively low testosterone levels around 200-250 ng/dL), additional testosterone does not further stimulate prostate growth.
Current evidence suggests:
- TRT does not increase the risk of developing new prostate cancer in men without existing disease
- TRT may be cautiously considered even in men with treated, low-risk prostate cancer (under close urologic surveillance)
- PSA typically rises 0.3-0.5 ng/mL in the first 6-12 months of TRT, then stabilizes
- Any rapid PSA rise (>1.0 ng/mL in 6 months or velocity >0.75 ng/mL/year) warrants urologic evaluation
Monitoring Protocol
- Baseline PSA and digital rectal exam (for men >40)
- PSA at 3 months, 6 months, then annually
- Urologic referral for PSA >4.0 ng/mL or rapid rise
Psychological and Behavioral Risks
Testosterone influences mood, motivation, confidence, and social behavior. While most patients experience psychological improvements on TRT, risks exist:
- Irritability and aggression: More common at supraphysiologic levels; rare at physiologic doses
- Mood instability: Can occur during dose adjustments or with significant peaks and troughs (less common with daily or frequent dosing)
- Sleep disturbances: TRT can worsen or unmask obstructive sleep apnea. A sleep study is recommended for patients with risk factors (obesity, snoring, daytime sleepiness)
- Dependency concerns: While testosterone is not addictive in the traditional sense, many patients feel significantly worse when stopping after months or years of use. The HPG axis may take months to recover, creating a period of symptomatic withdrawal
Skin and Hair Risks
- Acne: Testosterone stimulates sebaceous gland activity. Acne affects 15-25% of TRT patients, particularly in the first 3-6 months. It's usually mild and manageable with topical treatments.
- Androgenic alopecia: TRT can accelerate male-pattern hair loss in genetically predisposed individuals. The conversion of testosterone to DHT (via 5-alpha reductase) drives this process. Options include finasteride, dutasteride, topical minoxidil, or dose reduction.
- Increased body hair: Common and generally considered a neutral or positive effect.
Liver Risks
Modern TRT formulations (injectable, transdermal, pellet) carry virtually no liver risk. The historical concern comes from oral methyltestosterone and other 17-alpha-alkylated oral androgens, which are hepatotoxic. These are no longer used in standard TRT protocols.
Oral testosterone undecanoate (Jatenzo) is the one FDA-approved oral testosterone that bypasses first-pass liver metabolism via lymphatic absorption, carrying minimal hepatic risk.
Risks Specific to Women on Testosterone
Testosterone therapy in women uses much lower doses (typically 5-10% of male doses) but carries unique risks:
| Risk | Likelihood | Reversibility | Prevention |
|---|---|---|---|
| Acne | Common (20-30%) | Fully reversible | Start low, titrate slowly |
| Hirsutism (facial hair) | Moderate (10-20%) | Partially reversible | Monitor levels, keep in range |
| Voice deepening | Rare at physiologic doses | May be permanent | Keep total T under 70 ng/dL |
| Clitoral enlargement | Rare | May be permanent | Avoid supraphysiologic dosing |
| Androgenic alopecia | Uncommon (5-10%) | Variable | Monitor DHT, use low doses |
The Comprehensive TRT Monitoring Protocol
The single most effective way to minimize TRT risks is comprehensive, regular monitoring. Here is the protocol we recommend:
| Lab Test | Baseline | 6 Weeks | 3 Months | 6 Months | Annually |
|---|---|---|---|---|---|
| Total testosterone | ✓ | ✓ | ✓ | ✓ | ✓ |
| Free testosterone | ✓ | ✓ | ✓ | ✓ | ✓ |
| Estradiol (sensitive) | ✓ | ✓ | ✓ | ✓ | ✓ |
| SHBG | ✓ | ✓ | ✓ | ||
| CBC with hematocrit | ✓ | ✓ | ✓ | ✓ | ✓ |
| CMP (liver/kidney) | ✓ | ✓ | ✓ | ||
| Lipid panel | ✓ | ✓ | ✓ | ||
| PSA (men >40) | ✓ | ✓ | ✓ | ✓ | |
| LH/FSH | ✓ | ✓ | ✓ | ||
| DHEA-S | ✓ | ✓ |
A Functional Medicine Approach to Risk Reduction
Beyond lab monitoring, functional medicine offers additional strategies to reduce TRT risks:
- Optimize body composition: Lower body fat reduces aromatization (testosterone → estrogen conversion), lowering estrogen-related risks
- Support liver detoxification: Cruciferous vegetables, DIM, calcium-d-glucarate, and adequate fiber support healthy estrogen metabolism
- Ensure micronutrient adequacy: Zinc (supports testosterone metabolism), magnesium (reduces SHBG), vitamin D (supports HPG axis), boron (may modulate SHBG and free T)
- Address sleep apnea: Screen and treat before or concurrently with TRT initiation
- Manage stress: Chronic HPA axis activation increases cortisol, which antagonizes testosterone and promotes visceral fat accumulation
- Regular cardiovascular exercise: Improves lipid profiles, insulin sensitivity, and hematocrit regulation
The Bottom Line
Testosterone replacement therapy is neither a miracle nor a danger. It is a powerful clinical tool that, when used appropriately — at physiologic doses, with proper patient selection, and with regular monitoring — carries a favorable risk-to-benefit ratio for most patients with documented hypogonadism.
The risks are real but manageable. Polycythemia requires monitoring. Fertility suppression requires planning. Estrogen management requires attention. Cardiovascular safety requires baseline assessment. And all of it requires a practitioner who understands these nuances and monitors accordingly.
The greatest risk of TRT may actually be poor medical oversight — either from clinics that prescribe without adequate monitoring, or from practitioners who refuse to prescribe despite clear clinical need.
Concerned about the risks of testosterone therapy? Our clinical team provides comprehensive risk assessment, individualized dosing, and ongoing monitoring to ensure your hormone therapy is both effective and safe.
Get your free wellness blueprint
Already have your blueprint? Find a practitioner who specializes in your needs.
Frequently Asked Questions
Does testosterone replacement therapy cause heart attacks?
The TRAVERSE trial (2023), the largest randomized controlled trial on TRT safety, found no increased risk of major cardiovascular events in men with hypogonadism and pre-existing or high cardiovascular risk. Physiologic-dose TRT appears cardiovascularly safe with proper monitoring. Supraphysiologic doses do increase risk.
Can TRT cause blood clots?
TRT-induced polycythemia (elevated hematocrit) increases blood viscosity and clot risk. This is detectable through routine CBC monitoring and manageable with dose adjustment or therapeutic phlebotomy. The absolute risk is low with proper monitoring.
Will testosterone therapy make me infertile?
TRT suppresses sperm production in most men, and approximately 40-60% become azoospermic. Fertility usually recovers 6-12 months after stopping, but recovery is not guaranteed. Men desiring future fertility should consider alternatives like clomiphene citrate or bank sperm before starting.
Does TRT cause prostate cancer?
Current evidence does not support a causal link between physiologic-dose TRT and prostate cancer development. The saturation model suggests prostate tissue is maximally stimulated at relatively low testosterone levels. Regular PSA monitoring remains important.
What are the risks of testosterone therapy for women?
At physiologic female doses (typically producing levels of 30-70 ng/dL), risks include acne, hirsutism, and rarely voice deepening or hair thinning. Voice deepening and clitoral enlargement may be irreversible if they occur. Proper dosing and monitoring minimize these risks.
Can you stop TRT once you start?
Yes, but your natural testosterone production may take 3-12 months to recover, and some men (especially after years of use) may not fully recover to pre-TRT levels. A post-cycle recovery protocol using clomiphene or hCG can help restore the HPG axis.
Is TRT safe long-term?
Long-term safety data is encouraging but not definitive. Men who have been on physiologic-dose TRT for 10-20+ years with proper monitoring generally maintain favorable health profiles. The key is consistent monitoring and dose optimization throughout treatment.
Does TRT affect sleep?
TRT can worsen or unmask obstructive sleep apnea (OSA) in predisposed individuals. If you snore, have daytime sleepiness, or carry excess weight, a sleep study before starting TRT is recommended. TRT itself often improves sleep quality in men without OSA.